NCT03281096View on ClinicalTrials.gov

A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

1,000

Participants

Timeline

Start Date

August 29, 2017

Primary Completion Date

October 12, 2020

Study Completion Date

March 1, 2021

Conditions

Colorectal Adenomas

Interventions

DRUG

Berberine hydrochloride

patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.

DRUG

Placebo

pill manufactured to mmic Berberine hydrochloride 100mg tablet

Trial Locations (1)

710032

Xijing Hospital of Digestive Disease, Xi'an

All Listed Sponsors

lead

Xijing Hospital of Digestive Diseases

OTHER

NCT03281096 - A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer | Biotech Hunter | Biotech Hunter